Skip to main content
SpringerLink
Log in

Etanercept

A Review of its Use in the Management of Ankylosing Spondylitis and Psoriatic Arthritis

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Etanercept (Enbrel®), a recombinant, dimeric, soluble tumour necrosis factor (TNF) receptor protein, is approved in various countries for the treatment of adult patients with ankylosing spondylitis or psoriatic arthritis.

Monotherapy with subcutaneous etanercept 25mg twice weekly or 50mg once weekly was effective and generally well tolerated in patients with ankylosing spondylitis or psoriatic arthritis participating in several large, well designed clinical studies. Treatment with etanercept was more effective than placebo in reducing disease activity and improving health-related quality of life (HR-QOL) in both patient populations, and in delaying structural disease progression in patients with psoriatic arthritis. The beneficial response to etanercept achieved with shorter-term treatment was sustained in studies of up to 4 years’ total duration. Randomised, well designed, head-to-head comparisons, including pharmacoeconomic analyses, with other anti-TNF biological modulators are required to accurately position etanercept and fully establish its cost effectiveness. In the meantime, etanercept is a valuable treatment option for patients with ankylosing spondylitis or psoriatic arthritis who are suitable candidates for therapy.

Pharmacological Properties

Etanercept is a recombinant, dimeric, soluble TNF receptor protein. By competitively inhibiting the binding of two pro-inflammatory cytokines — TNFα and TNFβ (lymphotoxin) — to membrane-bound receptors, etanercept renders them biologically inactive and thus modulates the biological responses they induce or regulate.

Subcutaneous etanercept therapy generally had beneficial effects on biological markers of cartilage degradation/turnover in patients with ankylosing spondylitis or psoriatic arthritis. In patients with ankylosing spondylitis, etanercept treatment significantly reduced levels of serum matrix metalloproteinase-3, human cartilage glycoprotein-39 (both markers of cartilage degradation/turnover) and C2C (a marker of type II collagen degradation), and elevated levels of serum 846 epitope (a marker of proteoglycan aggrecan turnover). It also significantly increased the proportion of interferon-γ- and TNFα-producing CD4+ and CD8+ T cells. In patients with psoriatic arthritis, etanercept therapy reduced the expression of circulating osteoclast precursor levels and had a significant effect on the activation of a number of intracellular pathways associated with the signalling of cytokines such as TNFα or interleukin-1.

Etanercept is slowly absorbed from the site of subcutaneous injection and appears to be widely distributed throughout the body, including bone, kidney, liver, spleen and synovial fluid. After binding to TNFα, etanercept is believed to be metabolised by proteolytic processes in the body in the same way as other proteins; the by-products are then either recycled or eliminated in the urine and/or bile. Etanercept is slowly cleared from the body and has a long half-life, thereby allowing once- (50mg dose) or twice- (25mg dose) weekly administration.

Therapeutic Efficacy

Subcutaneous etanercept, at the recommended dosages, effectively improved clinical outcomes in patients with ankylosing spondylitis or psoriatic arthritis, and delayed radiographic disease progression in patients with psoriatic arthritis. Shorter-term (≤24 weeks) therapy with etanercept 25mg twice weekly or 50mg once weekly was better than placebo in reducing disease activity, according to the primary endpoints (Assessments in Ankylosing Spondylitis [ASAS] 20% improvement response rates in patients with ankylosing spondylitis; American College of Rheumatology [ACR] 20% improvement criteria and Psoriatic Arthritis Response Criteria [PsARC] in patients with psoriatic arthritis). Placebo-adjusted response rates were 31–37% in patients with ankylosing spondylitis (ASAS20), and 44% (ACR20) and 64% (PsARC) in patients with psoriatic arthritis. Noninferiority between the two etanercept dosages was established in a 12-week double-blind study in patients with ankylosing spondylitis. Furthermore, in general, etanercept therapy was significantly more effective than placebo treatment in terms of secondary endpoints, including ASAS 20%, 40%, 50% and 70% improvement response rates in patients with ankylosing spondylitis, and PsARC and ACR 20%, 50% and 70% improvement response rates in patients with psoriatic arthritis.

The shorter-term benefits of etanercept 25mg twice weekly were sustained during longer-term treatment in patients with ankylosing spondylitis (≤212 weeks’ total duration) and those with psoriatic arthritis (≤96 weeks’ total duration). Moreover, etanercept 25mg twice weekly delayed radiographic disease progression in a longer-term study in patients with psoriatic arthritis. In those with ankylosing spondylitis, longer-term etanercept therapy improved spinal mobility measures and reduced active spinal inflammation.

Recommended dosages of etanercept significantly improved the shorter- and longer-term HR-QOL of patients with ankylosing spondylitis or psoriatic arthritis versus placebo.

Pharmacoeconomic Considerations

A fully published modelled pharmacoeconomic analysis, conducted from a UK National Health Service perspective, predicted subcutaneous etanercept to be dominant (i.e. more effective and less costly), regardless of gender, time horizon or ‘rebound scenario’, over infliximab 5 mg/kg in patients with psoriatic arthritis. Furthermore, modelled analyses generally estimated etanercept to be more costeffective than infliximab or standard care in the treatment of ankylosing spondylitis or psoriatic arthritis.

Tolerability

Recommended dosages of subcutaneous etanercept were generally well tolerated during the shorter- (≤24 weeks) and longer- (≤96 weeks’ total duration) term treatment of patients with ankylosing spondylitis or psoriatic arthritis. The nature and incidence of treatment-emergent adverse events were generally similar to those in the placebo groups. Injection-site reactions, however, were consistently reported in significantly more etanercept 25mg twice weekly than placebo recipients. The majority of treatment-emergent adverse events and laboratory abnormalities were mild to moderate in severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kataria RK, Brent LH. Spondyloarthropathies. Am Fam Physician 2004 Jun 15; 69(12): 2853–60

    PubMed  Google Scholar 

  2. Sieper J, Braun J. Anti-TNF agents for the treatment of spondyloarthropathies. Expert Opin Emerg Drugs 2002; 7(2): 235–46

    Article  PubMed  CAS  Google Scholar 

  3. Baraliakos X, Braun J. Current concepts in the therapy of the spondyloarthritides. Biodrugs 2004; 18(5): 307–14

    Article  PubMed  CAS  Google Scholar 

  4. Gladman DD, Mease PJ. Towards international guidelines for the management of psoriatic arthritis. J Rheumatol 2006 Jul; 33(7): 1228–30

    PubMed  Google Scholar 

  5. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006 Jul; 33(7): 1417–21

    PubMed  Google Scholar 

  6. Goldsmith DR, Wagstaff AJ. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005; 6(2): 121–36

    Article  PubMed  Google Scholar 

  7. Mease PJ. Psoriatic arthritis therapy advances. Curr Opin Rheumatol 2005 Jul; 17(4): 426–32

    Article  PubMed  CAS  Google Scholar 

  8. De Keyser F, Baeten D, Van den Bosch F, et al. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis. Drugs 2004; 64(24): 2793–811

    Article  PubMed  Google Scholar 

  9. TNF antagonists for ankylosing spondylitis. Drug Ther Bull 2005 Mar; 43(3): 19–22

    Article  Google Scholar 

  10. Tobin AM, Kirby B. TNF-alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. Biodrugs 2005; 19(1): 47–57

    Article  PubMed  CAS  Google Scholar 

  11. European Medicines Agency. Enbrel: European Public Assessment Report (EPAR) [online]. Available from URL: www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrel.htm [Accessed 2007 Jan 20]

  12. Immunex Corporation. ENBREL® (etanercept): US prescribing information [online]. Available from URL: http://www.wyeth.com [Accessed 2007 Jan 20]

  13. McCormack PL, Wellington K. Etanercept: in ankylosing spondylitis. Biodrugs 2004; 18(3): 199–205

    Article  PubMed  CAS  Google Scholar 

  14. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002; 62(17): 2493–537

    Article  PubMed  CAS  Google Scholar 

  15. Dhillon S, Lyseng-Williamson KA, Scott LJ. Etanercept: a review of its use in the management of rheumatoid arthritis. Drugs 2007; 67(8): 1211–41

    Article  PubMed  CAS  Google Scholar 

  16. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57(6): 945–66

    Article  PubMed  CAS  Google Scholar 

  17. European Medicines Agency. Enbrel: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrel.htm [Accessed 2006 Jan 20]

  18. Davis JC, Webb A, Buenviaje H, et al. Etanercept suppresses serological markers of articular cartilage degradation/turnover in patients with ankylosing spondylitis (AS) [abstract no. FRI0152]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 242

    Google Scholar 

  19. Ritchlin CT, Haas-Smith SA, Shao T, et al. Etanercept lowers the frequency of circulating osteoclast precursors (OCP) and improves bone marrow edema in patients with erosive psoriatic arthritis. Arthritis Rheum 2003 Dec; 48(12): 3660–1

    Google Scholar 

  20. Lories RJ, Derese I, Luyten FP, et al. Synovial signaling pathway analysis reveals a heterogenous response after etanercept therapy in psoriatic arthritis. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 107–8

    Google Scholar 

  21. Maksymowych WP, Poole AR, Hiebert L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005 Oct; 32(10): 1911–7

    PubMed  CAS  Google Scholar 

  22. Zou J, Rudwaleit M, Brandt J, et al. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003 Jun; 62(6): 561–4

    Article  PubMed  CAS  Google Scholar 

  23. Zou J, Rudwaleit M, Brandt J, et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48(3): 780–90

    Article  PubMed  CAS  Google Scholar 

  24. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24(3): 518–23

    PubMed  CAS  Google Scholar 

  25. Woo JH, Lee HJ, Sung IH, et al. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007 Aug; 34(8): 1753–9

    PubMed  CAS  Google Scholar 

  26. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002 May; 346(18): 1349–56

    Article  PubMed  CAS  Google Scholar 

  27. Zhou H, Buckwalter M, Boni J, et al. Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2004 May; 42(5): 267–76

    PubMed  CAS  Google Scholar 

  28. Don BR, Spin G, Nestorov I, et al. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol 2005 Nov; 57(11): 1407–13

    Article  PubMed  CAS  Google Scholar 

  29. Zhou H, Parks V, Patat A, et al. Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol 2004 Nov; 44(11): 1244–51

    Article  PubMed  CAS  Google Scholar 

  30. Zhou H, Patat A, Parks V, et al. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol 2004 May; 44(5): 543–50

    Article  PubMed  Google Scholar 

  31. Calin A, Dijkmans BAC, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004 Dec; 63(12): 1594–600

    Article  PubMed  CAS  Google Scholar 

  32. Davis Jr JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003 Nov; 48(11): 3230–6

    Article  PubMed  CAS  Google Scholar 

  33. van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006 Dec; 65(12): 1572–7

    Article  PubMed  Google Scholar 

  34. Impastato R, Ciccia F, Ferrante A, et al. Infliximab and etanercept are both effective and safe in patients with ankylosing spondylitis: a two-year randomised study [abstract no. FRI0395]. Ann Rheum Dis 2007 Jun; 66 Suppl. II: 399

    Google Scholar 

  35. Immunex Corporation. Etanercept for the treatment of ankylosing spondylitis: Advisory Committee meeting clinical review briefing document [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3967B2_02_FDA-Embrel.pdf [Accessed 2004 Mar 15]

  36. van der Heijde D, da Silva J, Dougados M, et al. Once-weekly 50-mg dosing of etanercept is as effective as twice-weekly dosing in patients with ankylosing spondylitis [abstract no. SAT0195]. Ann Rheum Dis 2006 Jul; 65 Suppl. II: 509–10

    Google Scholar 

  37. Braun J, McHugh N, Singh A, et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007 Jun; 46(6): 999–1004

    Article  CAS  Google Scholar 

  38. Wyeth Pharmaceuticals. Enbrel: summary of product characteristics. Enbrel 25mg powder and solvent for solution for injection [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Nov 11]

  39. Davis JC, Van Der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005 Nov; 64(11): 1557–62

    Article  PubMed  CAS  Google Scholar 

  40. Sieper J, Dijkmans BAC, Van der Linden S, et al. Long term efficacy and safety of etanercept in patients with ankylosing spondylitis: 148 to 160 week analysis from an ongoing trial [abstract no. FRI0508]. Ann Rheum Dis 2006 Jul; 65 Suppl. II: 437–8

    Google Scholar 

  41. Sieper J, Dijkmans BAC, van der Linden S, et al. Sustained efficacy and safety of patients with ankylosing spondylitis treated with etanercept: outcomes at 148–160 weeks of long term therapy [abstract no. 1120]. Arthritis Rheum 2006 Sep; 54 Suppl. 9: S473

    Google Scholar 

  42. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005 Mar; 44(3): 342–8

    Article  CAS  Google Scholar 

  43. Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005 Dec; 53(6): 856–63

    Article  PubMed  CAS  Google Scholar 

  44. Dijkmans BAC, Sieper J, van der Linden S, et al. Long term efficacy and safety results and patient-reported outcomes in patients with ankylosing spodylitis treated with etanercept for 4 years [abstract no. FRI0383]. Ann Rheum Dis 2007 Jun 13; 66 Suppl. II: 395

    Google Scholar 

  45. Davis Jr JC, van der Heijde D, Braun D, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis [abstract no. FRI0378]. Ann Rheum Dis 2007 Jun 13; 66 Suppl. II: 393–4

    Google Scholar 

  46. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003 Jun; 48(6): 1667–75

    Article  PubMed  CAS  Google Scholar 

  47. Baraliakos X, Davis J, Tsuji W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005 Apr; 52(4): 1216–23

    Article  PubMed  CAS  Google Scholar 

  48. Rudwaleit M, Baraliakos X, Listing J, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005 Sep; 64(9): 1305–10

    Article  PubMed  CAS  Google Scholar 

  49. Dijkmans BAC, Wanders A, Van Der Heijde D, et al. Radio-graphic results from a long-term multicenter trial of etanercept (ENBREL Rm) in patients with ankylosing spondylitis [abstract no. 1708]. Arthritis Rheum 2005 Sep; 52 Suppl. 9: 634

    Google Scholar 

  50. van der Heijde D, Landewe R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005 Jul; 52(7): 1979–85

    Article  PubMed  Google Scholar 

  51. van der Heijde DM, Landewe RDM, Ory P, et al. Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis [abstract no. OP0090]. Ann Rheum Dis 2006 Jul; 65 Suppl. II: 81

    Google Scholar 

  52. Singh A, McHugh N, Wajdula JS, et al. Significant improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept [abstract no. SAT0501]. Ann Rheum Dis 2006 Jul; 65 Suppl. II: 602

    Google Scholar 

  53. Boonen A, Maetzel A, Patel V, et al. Etanercept in ankylosing spondylitis results in a rapid and sustained improvement in quality of life and utility: 72-week results from an open-label extension trial [abstract no. THU0532]. Ann Rheum Dis 2006 Jul; 65 Suppl. II: 276–7

    PubMed  Google Scholar 

  54. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000 Jul; 356(9227): 385–90

    Article  PubMed  CAS  Google Scholar 

  55. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004 Jul; 50(7): 2264–72

    Article  PubMed  CAS  Google Scholar 

  56. Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatol Treat 2006 Dec; 17(6): 343–52

    Article  CAS  Google Scholar 

  57. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006 Sep; 10(31): 1–258

    PubMed  CAS  Google Scholar 

  58. Lebwohl M, Gottlieb A, Mease P, et al. Etanercept improves psoriasis activity in patients with psoriatic arthritis: results of a phase 3 multicenter clinical trial [abstract no. P561 plus poster]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22–27; New Orleans (LA)

  59. Lebwohl M, Gottlieb A, Goffe BS, et al. Etanercept in psoriatic arthritis: sustained improvement in skin and joint disease and inhibition of radiographic progression at 2 years [abstract no. P2753]. J Am Acad Dermatol 2005 Mar; 52 Suppl. 3: 184. Plus poster presented at the 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18–22; New Orleans (LA)

    Google Scholar 

  60. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006 Apr; 33(4): 712–21

    PubMed  CAS  Google Scholar 

  61. Mease PJ, Gottlieb A, Woolley JM, et al. Sustained improvements in patient-reported outcomes in psoriatic arthritis patients treated with etanercept [abstract no. P5]. J Am Acad Dermatol 2005 Mar; 52 Suppl. 3: 2. Plus poster presented at the 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18–22; New Orleans (LA)

    Google Scholar 

  62. Mease PJ, Gottlieb AB, Yu EB, et al. Psoriatic arthritis patients treated with etanercept experience sustained improvements in physical function [abstract no. FRI0217]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 322

    Google Scholar 

  63. Mease PJ, Woolley M, Singh A, et al. Patient-reported outcomes in a randomized comparison of etanercept and placebo for treatment of psoriatic arthritis [abstract no. SAT0279]. Ann Rheum Dis 2006 Jul; 65 Suppl. II: 535

    Google Scholar 

  64. Wanke LA, Mease P, Gottlieb A, et al. Sustained improvement in activities of daily living and vitality in patients with psoriatic arthritis treated with etanercept [abstract no. P565]. J Am Acad Dermatol 2004 Mar; 50 Suppl. 3: 145. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6–11; Washington, DC

    Article  Google Scholar 

  65. Frankel EH, Fivenson D, Yu EB, et al. Improvements in patient-reported outcomes in psoriatic arthritis patients on etanercept: Results from EDUCATE, an open-label study of etanercept patients treated by dermatologists [abstract no. FRI0230]. Ann Rheum Dis 2005 Jul; 64 Suppl. Ill: 326

    Google Scholar 

  66. Frankel EH, Fivenson DP, Yu EB, et al. Improvements in health-related quality of life in psoriatic arthritis patients on etanercept: results from EDUCATE, an open-label study of etanercept patients treated by dermatologists [abstract no. P2765]. J Am Acad Dermatol 2005 Mar; 52 Suppl. 3: 188. Plus poster presented at the 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18–22; New Orleans (LA)

    Google Scholar 

  67. Frankel EH, Strober BE, Crowley JJ, et al. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 2007 Apr; 79(4): 322–6

    PubMed  Google Scholar 

  68. Boonen A, Van Der Heijde D, Severens JL, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006 Feb; 65(2): 201–8

    Article  PubMed  CAS  Google Scholar 

  69. Bravo Vergel Y, Hawkins NS, Claxton K, et al. The costeffectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford) 2007 Nov; 46(11): 1729–35

    Article  Google Scholar 

  70. Chiou F. Psoriatic arthritis patients treated with etanercept have reductions in caregiver burden, health care resource utilization, and absenteeism. J Manage Care Pharm 2006 Mar; 12(2): 193–4

    Google Scholar 

  71. Jackson JM, Boh E, Eisen D, et al. Psoriatic arthritis patients treated with etanercept had reductions in healthcare resource utilization: results from the Experience Diagnosing, Understanding Care, and Treatment with Enbrel (EDUCATE) Trial [abstract no. P2781]. J Am Acad Dermatol 2005 Mar; 52 Suppl. 3: 192. Plus poster presented at the 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18–22; New Orleans (LA)

    Google Scholar 

  72. Duff SB, Yeh Y, Yu EB, et al. The economic impact of etanercept and infliximab treatment in ankylosing spondylitis [abstract no. FRI0474]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 400. Plus poster presented at the Annual European Congress of Rheumatology (EULAR); 2005 Jun 8–11; Vienna

    Google Scholar 

  73. Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford) 2007 Aug; 46(8): 1338–44

    Article  CAS  Google Scholar 

  74. Sadri H, Mittmann N, Chau D, et al. Cost-effectiveness of TNF-alpha inhibitors in the treatment of ankylosing spondylitis in a Canadian setting [abstract no. 1789]. Arthritis Rheum 2005 Sep; 52 Suppl. 9: 663

    Google Scholar 

  75. Yu EB, Woolley JM. A cost-efficacy analsysis of etanercept and infliximab in the treatment of psoriatic arthritis [abstract no. FRI0473]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 400. Plus poster presented at Annual European Congress of Rheumatology (EULAR); 2005 Jun 8–11; Vienna

    Google Scholar 

  76. Parekh HH, Kamal KM. Economic evaluation of tumor necrosis factor inhibitors in the treatment of ankylosing spondylitis [abstract no. PAR4]. Value Health 2007 May–Jun; 10(3): A118

    Article  Google Scholar 

  77. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005 Aug; 52(8): 2447–51

    Article  PubMed  CAS  Google Scholar 

  78. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006 Dec; 65(12): 1631–4

    Article  PubMed  CAS  Google Scholar 

  79. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006 Dec; 113(12): 2317–23

    Article  PubMed  Google Scholar 

  80. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007 May 15; 57(4): 639–47

    Article  PubMed  CAS  Google Scholar 

  81. Keat A, Barkham N, Bhalla A, et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis: report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) 2005 Jul; 44(7): 939–47

    Article  CAS  Google Scholar 

  82. Kyle S, Chandler D, Griffiths CEM, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005 Mar; 44(3): 390–7

    Article  CAS  Google Scholar 

  83. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005 Mar; 64 Suppl. 2: ii74–7

    Article  PubMed  CAS  Google Scholar 

  84. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003 Sep; 62(9): 817–24

    Article  PubMed  CAS  Google Scholar 

  85. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006 Apr; 65(4): 442–52

    Article  PubMed  CAS  Google Scholar 

  86. Braun J, Baraliakos X, Brandt J, et al. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 2005 May–Jun; 34(3): 178–90

    CAS  Google Scholar 

  87. Kavanaugh A, Tutuncu Z, Catalan-Sanchez T. Update on antitumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 2006 Jul; 18(4): 347–53

    PubMed  CAS  Google Scholar 

  88. McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ 2006 Sep; 333(7568): 581–5

    Article  PubMed  Google Scholar 

  89. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006 Mar; 65(3): 316–20

    Article  PubMed  CAS  Google Scholar 

  90. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007 Nov; 66 Suppl. III: iii2–22

    Article  PubMed  CAS  Google Scholar 

  91. European Medicines Agency. Humira: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/humira/humira.htm [Accessed 2007 Feb 14]

  92. European Medicines Agency. Remicade: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/remicade/remicade.htm [Accessed 2007 Feb 14]

  93. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004; 27(5): 307–24

    Article  PubMed  CAS  Google Scholar 

  94. Schwartzman S, Morgan Jr GJ. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 2004; 6 Suppl. 2: S19–23

    Article  PubMed  CAS  Google Scholar 

  95. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol 2006 Mar; 54 (3 Suppl. 2): S85–91

    Article  PubMed  Google Scholar 

  96. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005 Mar; 64 Suppl. 2: ii78–82

    Article  PubMed  CAS  Google Scholar 

  97. National Institute for Health and Clinical Excellence. Etanercept and infliximab for the treatment of psoriatic arthritis [online]. Available from URL: http://www.nice.org.uk/guidance/TA104 [Accessed 2007 Feb 14]

  98. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 May 17; 295(19): 2275–85

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Sheridan M. Hoy & Lesley J. Scott

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Sheridan M. Hoy & Lesley J. Scott

Authors
  1. Sheridan M. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheridan M. Hoy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoy, S.M., Scott, L.J. Etanercept. Drugs 67, 2609–2633 (2007). https://doi.org/10.2165/00003495-200767170-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767170-00009

Keywords

Search

Navigation